Impulsivity: Current and future trends in pharmacological treatment

Expert Review of Neurotherapeutics

Volumn 10, Issue 9, 2010, Pages 1367-1369

  Braquehais, María Dolores ^a   Ramos Quiroga, J Antoni ^a   Sher, Leo ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

aggression; impulsivity; psychopharmacology; self harm; suicide

Indexed keywords

4 AMINOBUTYRIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; GLUTAMIC ACID; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROPEPTIDE; NEUROSTEROID; NORADRENALIN; OPIATE DERIVATIVE; OXYTOCIN; SEROTONIN UPTAKE INHIBITOR; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VASOPRESSIN;

AGGRESSION; BEHAVIOR DISORDER; BORDERLINE STATE; BRAIN REGION; DRUG EFFICACY; EDITORIAL; GABAERGIC SYSTEM; HUMAN; IMPULSIVENESS; LIMBIC CORTEX; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PERSONALITY DISORDER; PREFRONTAL CORTEX; UNSPECIFIED SIDE EFFECT;

BRAIN CHEMISTRY; HUMANS; IMPULSIVE BEHAVIOR; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 77956478129     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.100     Document Type: Editorial

References (22)

1. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am. J. Psychiatry 158(11), 1783-1793 (2001).
2. Dickman SJ. Functional and dysfuncitional impulsivity: personality and cognitive correlates. J. Pers. Soc. Psychol. 58, 95-102 (1990).
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, DC, USA (2005)
4. WHO. The ICD Classifcation of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland (2000).
5. Zuckerman M. P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. Neuropsychobilogy 28(1-2), 30-36 (1993).
6. Kertzman S, Grinspan H, Birger M, Kotler M. Computerized neuropsychological examination of impulsiveness: a selective review. Isr. J. Psychiatry Relat. Sci. 43(2), 74-80 (2010).
7. Baud P. Personality traits as intermediary phenotypes in suicidal behavior: genetic issues. Am. J. Med. Genet. C Semin. Med. Genet. 133C(1), 34-42 (2005).
8. Mann JJ. A current perspective of suicide and attempted suicide. Ann. Intern. Med. 136, 302-311 (2002).
9. Mann JJ. The biology of impulsivity and suicidality. Psychiatr. Clin. North Am. 23(1), 11-25 (2000).
10. Siever LJ. Neurobiology of aggression and violence. Am. J. Psychiatry 165(4), 429-442 (2008).
11. Dalley JW, Marc AC, Economidou D, Robbins TW. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav. 90(2), 250-260 (2008).
12. Sher L, Stanley B. The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior. Arch. Suicide Res. 12(4), 299-308 (2008).
13. Braquehais MD, Oquendo MA, Baca-García E, Sher L. Is impulsivity a link between childhood abuse and suicide? Compr. Psychiatry 51(2), 121-129 (2010).
14. Siever LJ, Buchsbaum MS, New AS. D,l-Fenfuramine response in impulsivity personality disorders assessed with 18-F-Fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 20, 413-423 (1999).
15. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology 29(6), 1029-1039 (2004).
16. Gobbi G, Janiri L. Sodium-and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacolog y (Berl.) 185(2), 255-262 (2006).
17. Lafenêtre P, Chaouloff F, Marsicano G. Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system. Neuropharmacology 57(7-8), 715-721 (2009).
18. Marco EM, Adriani W, Canese R, Podo F, Viveros MP, Laviola G. Enhancement of endocannabinoid signalling during adolescence: modulation of impulsivity and long-term consequences on metabolic brain parameters in early maternally deprived rats. Phramacol. Biochem. Behav. 86(2), 334-345 (2007).
19. Stanley B, Siever LJ. The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am. J. Psychiatry 167(1), 24-39 (2010).
20. Bellino S, Paradiso E, Bogetto F. Effcacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 22(8), 671-692 (2008).
21. Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. OROS methylphenidate for the treatment of adults with attention-defcit/hyperactivity disorder. Expert Rev. Neurother. 9(8), 1121-1131 (2009).
22. Oades RD. Role of the serotonin system in ADHD: treatment implications. Expert Rev. Neurother. 7(10), 1357-1374 (2007).